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Background. Natural killer cells are an important component of the innate immune system. Anti-cancer therapies utilizing
monoclonal antibodies also rely on the cytotoxicity of NK cells for their effectiveness. Here, we study the dynamics of NK cell
cytotoxicity. Methodology/Principal Findings. We observe that IL-2 activated human NK cells can serially hit multiple
targets. Using functional assays, we demonstrate that on an average, a single IL-2 activated NK cell can kill four target cells.
Data using live video microscopy suggest that an individual NK cell can make serial contacts with multiple targets and majority
of contacts lead to lysis of target cells. Serial killing is associated with a loss of Perforin and Granzyme B content. A large
majority of NK cells survive serial killing, and IL-2 can replenish their granular stock and restore the diminished cytotoxicity of
‘exhausted’ NK cells. IL-2 and IL-15 are equally effective in enhancing the killing frequency of resting NK cells. Significantly,
Rituximab, a therapeutic monoclonal antibody increases the killing frequency of both resting and IL-2 activated NK cells.
Conclusion/Significance. Our data suggest that NK cell-based therapies for overcoming tumors rely on their serial killing
ability. Therefore, strategies augmenting the killing ability of NK cells can boost the immune system and enhance the
effectiveness of monoclonal antibody-based therapies.
Citation: Bhat R, Watzl C (2007) Serial Killing of Tumor Cells by Human Natural Killer Cells ?– Enhancement by Therapeutic Antibodies. PLoS ONE 2(3):
e326. doi:10.1371/journal.pone.0000326
INTRODUCTION
Natural killer cells are key players in eliminating and preventing
tumor growth [1]. They execute their cytotoxicity in a sequential
manner, which involves (i) formation of conjugate between NK
and tumor cell (ii) delivery of lethal hit (iii) disassociation of tumor
and NK cell. A disassociated NK cell can restart and bind to new
targets and finally eliminate them, commonly referred to as
recycling capacity or killing frequency [2]. In case of cytotoxic T
lymphocytes, it has been demonstrated that at a single cell level
a mouse effector lymphocyte can kill one target and has the
potential to recycle and kill up to six targets in a sequential manner
[3]. Computational models have attempted to explain kinetic
parameters of recycling capacity of effector cells [2,4,5]. Neverthe-
less, only little information exists about killing potential or
frequency of NK cells. How often, and how many targets a single
human NK cell can kill is still unknown. Knowledge regarding the
frequency of NK cell killing can prove helpful for devising novel
strategies to boost NK cell efficiency.
NK cells undergo functional anergy or exhaustion after carrying
out their killing action. Previous studies have demonstrated that
after an exposure to target cells, NK cells undergo inactivation,
loose their cytotoxic function and become apoptotic [6,7].
Cytotoxicity of NK cells is executed mainly through the granule
exocytosis pathway where Perforin and Granzyme B content of
granules is released into the immunological synapse after
conjugate formation with targets [8]. This results in a depletion
of these components and in a loss of cytotoxicity. Whether the
cytotoxic function and granular content of NK cells, which have
already participated in serial killing and have undergone in-
activation can be reversed is still unknown.
Strategies to augment NK cell activity for tumor immunother-
apy are actively pursued at present [9,10]. IL-2, IL-15 and IFN-
a have been implicated in NK cell activity, growth, development
and differentiation [11–13]. IL-15 has been shown to be a major
factor in development, increasing cytotoxicity and proliferation of
NK cells. Similarly, IL-2 has been used effectively in cancer
immunotherapy in clinical trials. IFN-a has been shown to
promote NK cell mediated cytotoxicity and defense against viral
infections. Stimuli that can enhance killing potential and frequency
of NK cells still need to be identified.
Studies exploring therapeutic monoclonal antibodies in poten-
tiating host immune responses against malignancies are being
pursued vigorously and have been successful [14]. Rituximab, one
widely studied therapeutic monoclonal antibody, is a chimeric
IgG1 monoclonal antibody that specifically targets CD20 surface
antigen expressed on normal and neoplastic B-lymphoid cells [15].
Rituximab has been shown to induce apoptosis, complement
mediated lysis and antibody-dependent cellular cytotoxicity in
vitro. The effectiveness of rituximab relies on the cytotoxic
function of NK cells [9,10,16,17]. Whether Rituximab enhances
the frequency of killing by NK cells is still unexplored.
In the present study we investigate the number of targets a single
IL-2 activated NK cell can eliminate. Our findings demonstrate
that similar to CTLs, NK cells can make multiple contacts and kill
serially in a time-dependent manner. A large majority of NK cells
survive after such serial killing and IL-2 has the potential to restore
the cytotoxicity and granular content of exhausted NK cells.
Rituximab treatment enhances the killing frequency of fresh and
IL-2 activated NK cells. Strategies resulting in increased serial
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of these strategically important immune cells.
RESULTS
NK cells can kill multiple targets
To explore the maximal killing potential of NK cells, we first
identified a tumor target most susceptible to NK cell lysis. We
therefore tested several target cell lines against IL-2 activated NK
cells and found that MHC-I negative 722.221 cells showed better
lysis that K562 targets and were most susceptible to NK cell killing
(data not shown). As effector cells we chose to use primary human
NK cells from healthy donors, which had been expanded in IL-2
for two weeks, as these cells showed maximal cytotoxic activity. To
determine the number of targets killed per individual NK cell, we
used a
51Cr release assay with an excess of target cells. This way
each NK cell has access to a large number of targets, making it
possible to estimate the maximal killing activity. We performed
standard 4 h and also 16 h
51Cr release assays to determine the
full potential of NK cell activity. Killing activity of NK cells was
assessed in terms of % specific lysis and the amount of target cells
lysed per NK cell (killing frequency) was determined by dividing
the number of killed targets by the number of effector cells (Fig. 1).
Killing frequency was inversely proportional to % specific lysis and
increased from higher to lower effector to target ratios. This is
probably be due to a greater possibility for an individual NK cell
to form contacts with target cells at lower effector to target ratios.
Analysis of the killing frequency of NK cells from multiple donors
demonstrates that on an average two or four targets are killed by
an NK cell after 4 or 16 hours, respectively (Fig. 1C). This suggests
that IL-2 activated NK cells are capable of making multiple
contacts and can kill multiple targets. To visualize the process of
serial killing, we employed time lapse video microscopy (Fig. 2).
Dye labeled NK cells were incubated with unlabeled 221 target
cells and observed under 16 hour time lapse microscopy. Sytox
dye was used to visualize dead cells. These data confirm that
a single NK cell can make serial contacts with multiple targets and
finally kill them. Most of the contact formations observed resulted
in killing (Fig. 2B). However, all NK cells were not equally active
in forming contacts and killing targets but few ‘hyperactive’ NK
cells were also observed, lysing up to 6 individual targets (Fig. 2
and data not shown). Interestingly, during the process of killing
only very few dead NK cells were detected.
Figure 1. IL-2 activated human NK cells can kill multiple targets. IL-2 activated primary human NK cells were co-incubated with
51Cr labeled 221 target
cells at an E:T ratio of 0.8:1 to 0.05:1 for 4 and 16 hours. (A) 51 Cr release assay was used to calculate % specific lysis for 4 and 16 hours duration. (B) %
specific lysis was used to calculate killing frequency by dividing the number of target cells killed by number of effector cells used for each E:T ratio. (C)
Killing frequency of IL-2 activated NK cells using four independent donors for 4 and 16 hours duration.
doi:10.1371/journal.pone.0000326.g001
Figure 2. Serial killing by an NK cell. (A) A single NK cell makes multiple
contacts with tumor cells resulting in lysis of tumor cells. Dye-labeled IL-
2 activated NK cells (N, red) were incubated with unlabelled 221 tumor
cells at an E:T ratio of 0.2:1 for 16 hours at 37uC and 5% CO2 and images
were recorded by time lapse microscopy. Dead cells were detected
using Sytox Green and numbered in the order of lysis. Time (h:mm) is
indicated in the upper left corner of each image. (B) Majority of
conjugate formations result in lysis. Conjugate formations between NK
and 221 cells were randomly selected and lysed target cells counted. To
rule out the possibility of interference of dyes in killing process, a control
51Cr release assay was performed with labeled cells. No difference was
noted between the killing ability of labeled and unlabeled cells (data
not shown).
doi:10.1371/journal.pone.0000326.g002
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Granzyme B but survive serial killing
Cytotoxicity of NK cells is mostly mediated by the release of
Perforin and Granzyme B [8]. To determine whether serial killing
is granule-mediated, we analyzed Perforin and Granzyme B
expression in NK cells after co-incubation with 221 cells using
intracellular flow cytometry. Data from multiple donors showed
that there was significant reduction in Perforin and Granzyme B
content after target cell contact (Fig. 3A). The decrease was more
prominent in case of Granzyme B than Perforin in all cases
observed. Interestingly, we never observed a complete loss of these
molecules even after prolonged target cell contact (data not
shown). Overall, these data suggests that serial killing by NK cells
is mediated by Perforin and Granzyme B.
To investigate whether NK cells survive or undergo apoptosis
after killing their targets, NK cells were incubated alone and with
221 targets for 16 hours. After incubation, cells were harvested
and stained for CD56 expression and with AnnexinV to identify
apoptotic cells (Fig. 3B). Gating on free NK cells showed only
a negligible fraction of apoptotic cells after target cell contact,
while a significant number of 221 cells were clearly apoptotic.
However, when gating on the conjugates between NK and 221
cells, we found around 25% of NK cells to be AnnexinV positive.
Overall we found 15% of total NK cells (free and in conjugates) to
be apoptotic after 16 h target cell contact. The large number of
apoptotic NK cells in the conjugate gate could be an artifact of the
conjugates where the NK cell contributes for the CD56 staining,
but only the attached 221 cell is AnnexinV positive. We therefore
treated the conjugates with EDTA for 15 min. at 37uC to dis-
sociate them. EDTA treatment resulted in approximately 50% of
conjugates falling apart and also reduced the number of AnnexinV
positive NK cells (data not shown). This demonstrates that at least
some NK cells only appeared to be apoptotic because of an
attached AnnexinV positive 221 cell. However, a fraction of NK
cells still remained AnnexinV positive. Taken together, these
results suggest that majority of NK cells survive the killing process
and only a small number of NK cells undergo apoptosis and these
cells lie in the conjugate region.
IL-2 restores cytotoxicity and granular stock in NK
cells
As NK cells experience a reduction in the amount of Perforin and
Granzyme B after serially killing of tumor cells but survive the
process, we wanted to investigate whether the cytolytic ability of
these NK cells can be restored. We therefore incubated NK cells
alone or in combination with 221 cells for 16 hours. After that the
cells were harvested and CD56 positive NK cells were re-isolated
using MACS positive selection. The isolated NK cells were then
cultured in presence of IL-2 and killing activity was examined.
One day after isolation the NK cells recovered after target cell
incubation demonstrated a significant lower cytotoxicity against
221 target cells as compared to cells isolated from the control
fraction (Fig. 4A). However, the killing ability of these ‘exhausted’
NK cells was augmented in response to IL-2 treatment on day 2
and was similar to that of control NK cells (Fig. 4B). We also
determined Perforin and Granzyme B staining of these NK cells.
Perforin and Granzyme B content showed an increase after
isolation and culture with IL-2, correlating with the observed
increase in killing activity (data not shown).
IL-2 and IL-15 are equally effective in increasing
cytotoxicity of NK cells
In the experiments described above we used primary human NK
cells, which had been expanded in the presence of IL-2 for
2 weeks, as such cells showed a high cytotoxic activity. To test
whether other factors can modulate NK cell killing activity and
subsequently killing frequency, we stimulated freshly isolated
human NK cells with IL-2, IL-15, IFN-a or polyI:C for 7 days and
assessed their killing activity. Cells stimulated with low concentra-
Figure 3. Serial killing of tumor cells by NK cells is mediated by Perforin and Granzyme B. (A) IL-2 activated NK cells, alone (2221) or together with 221
target cells (+221) were incubated for a period of 16 hours at an E:T ratio of 0.2:1 and then stained intracellularly for Perforin and Granzyme B content.
NK cells were identified by gating on CD56 positive cells. Fold expression shown here represents the ratio of MFI of Perforin/Granzyme B and
respective isotypes. Figure is representative of multiple donors. (B) IL-2 activated NK cells were incubated alone or in combination with 221 targetsa t
an E:T ratio of 0.2:1. After 16 hours, cells were harvested and stained for CD56 expression (NK cells) and annexinV (apoptotic cells). NK and 221 cells
alone were used as controls. Forward and sideward scatter gating was used to gate on free NK cells, free 221 cells or conjugates. Figure is
representative of multiple donors.
doi:10.1371/journal.pone.0000326.g003
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cells cultured in the presence of 100 IU/ml of IL-2 (Fig. 5A). This
suggests that while low doses of IL-2 are sufficient for the survival
of NK cells, only higher doses can efficiently stimulate their
cytotoxicity. Next we stimulated NK cells with IL-2 or IL-15. Both
cytokines were found to be equally effective in increasing the
cytolytic ability of NK cells (Fig. 5B). However, no synergistic
effect was observed when IL-15 and IL-2 were used in
combination. IFN-a, polyI:C or CpG oligo nucleotides either
alone or in combination with IL-2 failed to induce any significant
difference in NK cell cytotoxicity when compared to IL-2
treatment alone (Fig. 5C and data not shown).
Rituximab increases killing frequency of NK cells
Monoclonal antibodies used for anti-cancer therapies can
effectively stimulate NK cell activity through the Fc receptor
CD16 [16,17]. To investigate whether a therapeutic antibody can
increase the killing frequency of freshly isolated NK cells, we
incubated 221 cells with Rituximab and used them as targets for
NK cells in a 4 and 16 h
51Cr release assay (Fig. 5D). While freshly
isolated NK cells were only poorly cytotoxic against control
treated 221 cells, their cytotoxic activity could be greatly enhanced
by using Rituximab-coated 221 cells as targets. This is consistent
with a previous report demonstrating that CD16 is sufficient to
trigger the cytotoxic activity of resting NK cells [18]. The use of
Rituximab-coated 221 cells resulted in the lysis of 2–3 targets per
NK cell in a 16 h assay. This demonstrates that even freshly
isolated NK cells have cytotoxic potential and are capable of serial
killing.
Figure 4. IL-2 restores the killing ability of inactivated NK cells. IL-2
activated NK cells were incubated with or without 221 targets for
16 hours at an E:T ratio of 0.2:1. Thereafter, NK cells were re-isolated by
CD56 positive selection using MACS columns and cultured in the
presence of IL-2 (100 U/ml). Killing assays against 221 target cells were
performed on day 1 (A) and 2 (B) after isolation. Data from three
independent donors show that NK cells regain their lost cytotoxic
ability on day 2 in response to IL-2 treatment.
doi:10.1371/journal.pone.0000326.g004
Figure 5. Increasing the killing frequency of fresh NK cells by cytokines and Rituximab. (A) Freshly isolated NK cells were cultured with IL-2 (10 or 100
U/ml) alone (A) or with IL-2 (100 U/ml) and IL-15 (10ng/ml), alone or in combination (B) IL-2 (100 U/ml) alone or in combination with IFN-a (1000U/ml)
or poly I:C (50 mg/ml) (C) for one week. Thereafter, stimulated NK cells were tested against 221 target cells using 4 hours Cr-
51 release assays.
Combining IFN-a or poly I:C with only 10 U/ml IL-2 also showed no enhancement of cytotoxicity (data not shown). (D) 221 target cells were treated
with Rituximab (10 mg/ml) and killing frequency of freshly isolated NK cells was assessed by 4 and 16 h
51Cr release assay and compared to untreated
targets. Data are representative of three independent experiments using NK cells from different donors.
doi:10.1371/journal.pone.0000326.g005
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the killing frequency of IL-2 activated NK cells, which were
already highly cytotoxic (Fig. 1). Rituximab treatment resulted in
a significant increase of NK cell cytolytic ability and consequently
also killing frequency, which was already obvious after 4 hours,
but most prominent after 16 hours of incubation with IL-2
activated NK cells (Fig. 6). Data from three independent donors
showed an increase of two fold in killing frequency as compared to
untreated target cells, reaching a maximum of 6 target cells killed
per NK cell after 16 hours (Fig. 6C). Control antibodies showed
no effect. We also analyzed the effect of Rituximab treatment on
the decrease of Perforin and Granzyme B content using
intracellular staining. Data from three donors showed further
reduction in Perforin and Granzyme B expression on coincubation
with rituximab treated targets as compared to untreated targets
(data not shown).
DISCUSSION
Natural killer cells are known to participate actively in combating
tumors. However, details about dynamics of NK cell cytotoxicity
are still lacking. How much potential a singe NK cell has to kill
and the number of hits it can deliver when encountered by
multiple targets is still unknown. Previous reports have attempted
to unravel the killing frequency of mouse CTLs under controlled
conditions and observed that a single CTL can eliminate up to six
targets [3]. Later various computational models, utilizing various
variables, were employed to deduce kinetics of binding of NK cells
to multiple targets and their recycling capacity, but no consensus
exists [2,4,5]. Moreover, these reports do not give any idea about
the killing frequency of a single NK cell. Our study attempts to
reveal the maximal potential of IL-2 activated human NK cells in
eliminating tumor cells.
From the
51Cr release data we conclude, that a single IL-2
activated NK cell can kill four 221 target cells in a 16 hour assay.
This calculation assumes, that the release of
51Cr is an accurate
measure about the number of target cells lysed. However, we
cannot exclude, that there is also unspecific or bystander lysis in
our assay, which would lead to an over estimation of the number
of target cells killed. We therefore employed time lapse microscopy
to directly demonstrate the serial killing of NK cells. Although we
did observe individual NK cells serially killing 4 or even more
targets, many NK cells only killed once or twice. It is not possible
to directly calculate the average killing capacity of NK cells from
this assay because of the experimental setup of the microscopy. We
could only use a limited concentration of cells in order to clearly
observe individual NK-target cell interactions. Therefore, not
every NK cell has even the chance to meet four or more targets in
this assay and we cannot expect to see the full killing potential of
all NK cells. However, most of the conjugate formations with the
target cells resulted in lysis. This is in contrast to a recent report,
demonstrating that almost 50% of the conjugates between IL-2
activated mouse NK cells and YAC-1 targets are non-productive
and dissociate without killing [19]. The reason for this discrepancy
might be the choice of target or the species origin of the NK cells.
The
51Cr release data can only give an average killing frequency
as the activity of many NK cells is assayed. In our time lapse
microscopy we observed some hyperactive NK cells, which were
more fervent in their killing spree, while other NK cells were much
more stationary, killing only one target. One possible explanation
for this observation is that there is heterogeneity among NK cells,
with some cells being much more active than others. This is also
reflected by the analysis of Perforin and Granzyme B content,
where we observed that some NK cells suffered a greater loss of
these effector molecules after target cell contact (Fig. 3A), possibly
due to higher activity and more lysis. It will be interesting to
analyze the nature of such hyperactive NK cells. This could lead
the way for selecting NK cells with especially high activity for NK
cell based therapies or enable us in the future to better stimulate
NK cell activity.
We observed that a single NK cell could make contacts to two
or more targets at the same time. However, the serial killing was
found to operate strictly in a sequential manner as we never
observed any simultaneous killing of two or more targets by a single
NK cell. Some NK cells also stayed attached to target cells after
lysis was complete. This was also observed in our FACS analysis
where we detected NK cells in conjugate with AnnexinV positive
target cells. It is interesting to speculate that the multiple target cell
contacts before and after lysis could enhance NK cell activation by
providing additional activating receptor engagement and NK cell
stimulation. Such uncoupling of lytic and stimulatory contacts has
recently been shown for cytotoxic T lymphocytes [20].
NK cells underwent a significant reduction in their Perforin and
Granzyme B content after target cell incubation. The loss of
Perforin during a single degranulation event of resting NK cells
was reported to be rather small [21]. Even four of such
degranulation events might not explain the significant reduction
in Perforin and Granzyme B we observed in our experiments. One
explanation for this might be that IL-2 activated NK cells are
Figure 6. Rituximab increases killing frequency of IL-2 activated NK cells. 221 target cells were treated with Rituximab (10 mg/ml) and killing
frequency of NK cells was assessed by 4 h (A) or 16 h (B)
51Cr release assay and compared to untreated or isotype treated targets. (C) Data from three
independent donors show that rituximab increases the killing frequency of NK cells two fold as compared to untreated target cells.
doi:10.1371/journal.pone.0000326.g006
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a single degranulation event. We never observed a complete loss of
Perforin and Granzyme B in exhausted NK cells. This
demonstrates that also other mechanisms besides the loss of
Perforin and Granzyme B are the reason for NK cell exhaustion.
Such mechanisms could be the down-modulation of activating
receptors [22] or the inactivation of signaling pathways due to
constant stimulation. The majority of such exhausted NK cells
survived the target cell contact and could even be re-activated by
IL-2 stimulation after separation from target cells. This suggests
that IL-2 is necessary not only for maintenance and survival of NK
cells but also important for the regeneration of inactivated NK
cells. The separation of NK cells from target cells may be crucial as
a previous report suggested that the cytotoxic activity of
inactivated NK cells could be enhanced by overnight IL-2
treatment when NK cells were dissociated from conjugates while
this was not possible with associated conjugates [7]. This is in line
with our finding that most apoptotic NK cells were found in
conjugate with 221 cells. Also an earlier study demonstrated that
inactivated and dead NK cells are restricted to conjugates between
NK and target cells [6]. The removal of apoptotic cells by
phagocytic cells in vivo may therefore play an important role in
keeping NK cells active.
Our and many previous data show that IL-2 is a very potent
stimulator of NK cell cytotoxicity. While IL-15 showed a similar
potency, we did not observe any synergistic effect when combining
IL-2 and IL-15. Also using IL-2 in combination with polyI:C or
CpG oligonucleotides to stimulate TLRs did not result in an
increased activity of NK cells. One explanation for this could be
that IL-2 or IL-15 induce already a maximal stimulation of NK
cells. However, fresh and IL-2 stimulated NK cells could be
further stimulated by engagement of CD16 through rituximab
coated target cells. It was surprising to see such an enhancement,
as the 221 cells represent already the most sensitive target cell for
IL-2 activated NK cells in our hands. The rituximab-mediated
enhancement of lysis was already very obvious in a 4 h assay. As
we do not expect to see any significant exhaustion of NK cells
during this short time frame, we speculate that rituximab either
enhances the speed by which an individual NK cell can lyse, or
stimulate previously inactive NK cells to kill. Also after 16 hours
we observed a clear enhancement of lysis by rituximab, almost
doubling the killing frequency of IL-2 activated NK cells. This
effect could again be mediated by stimulating previously inactive
NK cells. However, it is likely that rituximab increases the
potential of NK cells to hit multiple targets. In line with this
hypothesis we observed that rituximab treatment enhanced
degranulation of NK cells as evident by further reduction in
Perforin and Granzyme B content of NK cells. These data suggest
that therapeutic monoclonal antibodies against tumors may rely
on the serial killing of NK cells and strategies focusing on
enhancing the killing potential of NK cells are likely improve their
effectiveness.
MATERIALS AND METHODS
Cell culture, cell lines and cytokines
Human polyclonal NK cells were isolated by negative depletion
from peripheral blood lymphocytes (PBLs) using an NK-cell
isolation kit (Dynal, Karlsruhe, Germany). NK cells were between
90% and 99% CD3
2 and CD56
+. NK cells were expanded in the
presence of IL-2 and feeder cells as described (18,19). 721.221 cells
were grown in IMDM, 10% fetal calf serum, penicillin/
streptomycin (Invitrogen, Karlsruhe, Germany). Fresh NK cells
were stimulated without feeder cells in the presence of IL-2
(100 IU/ml) (NIH cytokine repository), IL-15 (10 ng/ml) (R&D
systems, Wiesbaden, Germany) and IFN-a (1000 IU/ml) or poly
I:C (50 mg/ml) (Sigma-Aldrich, Taufkirchen, Germany) for
1 week.
FACS analysis and antibodies
For surface staining, the cells were incubated with anti-CD56 PE
or FITC and CD19 FITC Abs (BD Biosciences, Heidelberg,
Germany) in 50 ml of FACS buffer (PBS, 2% FCS) for 20 min on
ice. All washing steps were performed with cold FACS buffer. For
intracellular staining, cells were first stained with cell surface mAb
as described, washed, and then fixed with 4% paraformaldehyde
for 15 min and permeabilized in PBS, 2% FCS, 0.5% saponin and
incubated with Perforin-FITC (BD Pharmingen, Heidelberg,
Germany) and Granzyme B PerCP (Caltag laboratories) for
30 min at 4uC. Cells were then washed and immediately analyzed
on a FACSCalibur. For analysis of apoptosis, cells were harvested,
surface stained, washed and centrifuged (1500 rpm, 5 min). The
cell pellets were suspended in 16binding buffer (10 mM HEPES,
pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). The cells were stained
using 5 ml each of annexin V-PE (BD Pharmingen, Heidelberg,
Germany), gently vortexed and incubated for 15 min at room
temperature. 400 ml of binding buffer was added before FACS
analysis.
Cytotoxicity assay
Target cells were grown to mid-log phase, and 5610
5 cells were
labeled in 100 ml of assay medium (IMDM with 10% FCS and
penicillin/streptomycin) with 100 m Ci
51Cr for 1 hr at 37uC. Cells
were washed twice and resuspended in assay medium. A total of
5000 target cells/well was used in the assay. Effector cells were
resuspended in assay medium, distributed on a V-bottom 96-well
plate, and mixed with labeled target cells at different E:T ratios.
Maximum release was determined by incubating target cells in 1%
Triton X-100. For spontaneous release, targets were incubated
without effectors in assay medium alone. In case of rituximab
treatment, target cells were incubated with Rituximab (Roche,
Mannheim, Germany) or a control antibody (MOPC-21 (Sigma,
Taufkirchen, Germany)) at a final concentration of 10 mg/ml. All
samples were done in triplicates, and IL-2 was used at 100 IU/ml
final concentration in the whole assay. After a 1 min centrifuga-
tion at 1000 rpm, plates were incubated for 4 and 16 h at 37uC.
Supernatant was harvested and
51Cr release was measured in
a gamma counter. Percentage of specific release was calculated as




6) cells were harvested, washed twice and resuspended
in 100 ml of diluent C (Fluorescent Red Linker Kit, Sigma,
Taufkirchen, Germany). Red dye (1:50), provided with the kit, was
added and cells incubated at RT for 5 min. 100 ml of heat-
inactivated FCS was added and incubated for 1 min to stop the
reaction. Thereafter, cells were washed with RPMI+10%FCS
thrice to remove unlabelled dye and then incubated for 2 hours at
37uC. After that cells were counted and co-incubated with
unlabelled 221 cells. Sytox Green nucleic acid stain (Invitrogen,
Karlsruhe, Germany) at a final concentration of 100 nm/ml was
used to detect dead cells. Cells were co-incubated in micro-
chambers (Lab-Tek Chambers cover-glasses, Nalgene Nunc,
Wiesbaden, Germany) and observed under Zeiss LSM-510 Time
Lapse microscope at 37uC and 5% CO2. Image sequences of time-
lapse recording were processed with METAMORP software.
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